Ahmad Taha, MD
Family Medicine · Miami, FLNPI 1396797312
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,524 of the $2,404 with a category attached, or 63.4%. 7 manufacturers reported payments, led by Medtronic at 35.1% of the total. Reporting peaked in 2019 at $1,112 and has fallen 70.4% since, to $329 in 2025.
Across 20 payments — averaging $120.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$844
- Covidien LP$813
- Johnson & Johnson$571
- La Jolla Pharmaceutical Company$125
- Kyowa Kirin, Inc.$20
- Astellas Pharma US Inc$17
- plus $15 from 1 others
What the payments were for
- Consulting fees$1,52463%
- Food & beverage$88137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $844 |
| Covidien LP | 1 | $813 |
| Johnson & Johnson(2 entities) | 13 | $571 |
| La Jolla Pharmaceutical Company | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Inari Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$145
- StealthStation$133
- Zevtera$125
- ECHELON ENDOPATH$107
- Enseal X1$107
- VISTASEAL$107
- PROLENE$107
How this compares
$2,404 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $11,313 |
| SynthroidLevothyroxine Sodium | 18 | $1,262 |
| Levothyroxine Sodium | 60 | $360 |
| Temazepam | 29 | $335 |
| Metoprolol Succinate | 48 | $327 |
| Rosuvastatin Calcium | 34 | $276 |
| Simvastatin | 59 | $265 |
| Famotidine | 44 | $250 |
| Memantine Hcl | 15 | $233 |
| Losartan Potassium | 65 | $233 |
| Atorvastatin Calcium | 34 | $165 |
| Glipizide | 14 | $154 |
| Omeprazole | 21 | $152 |
| Ketoconazole | 11 | $120 |
| Alendronate Sodium | 23 | $115 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.